Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a ...

However, that is less true for large-cap stocks like Merck and Bristol-Myers. Still, it’s important to understand why ...

We often say that terminations or attrition are a natural part of drug development. And as we've noted this year ... an ...

The collaboration with Merck KGaA, Darmstadt, Germany focuses on discovering ... stage biopharmaceutical company focused on ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...